share_log

Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5

Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5

Ladenburg Thalmann维持对UroGen药业的买入评级,将价格目标上调至53.5美元。
Benzinga ·  06/14 14:42

Ladenburg Thalmann analyst Matthew Kaplan maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $48 to $53.5.

Ladenburg Thalmann分析师Matthew Kaplan维持对UroGen Pharma(纳斯达克股票代码:URGN)的买入评级,将目标价从48美元上调至53.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发